Core Viewpoint - Aldeyra Therapeutics, Inc. is under investigation for potential violations of federal securities laws following the failure of its lead drug candidate reproxalap in clinical trials, leading to a significant decline in stock price [1][5]. Company Overview - Aldeyra Therapeutics is a biotechnology company focused on developing therapies for immune-mediated and metabolic diseases, with reproxalap as its lead drug candidate aimed at treating dry eye disease [2]. Clinical Trial Results - The company announced success in its Phase III clinical trial for reproxalap, claiming the results were "uniquely supportive" and met FDA requirements for New Drug Application resubmission [3]. - However, the trial ultimately failed to demonstrate the drug's efficacy in treating ocular symptoms associated with dry eyes, with methodological issues identified in the trial data [4]. Stock Market Reaction - Following the FDA's Complete Response Letter on April 3, 2025, which stated that the NDA for reproxalap did not demonstrate adequate efficacy, Aldeyra's stock price plummeted nearly 75% from $5.33 per share on April 2, 2025 [5].

Group 1 - Monteverde & Associates PC is investigating Coeptis Therapeutics Holdings, Inc. regarding its proposed merger with Z Squared Inc., where Z Squared shareholders will receive equity in Coeptis in exchange for 9,000 U.S. based dogecoin mining machines [1] - Monteverde & Associates PC has a successful track record in recovering millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] - The firm operates from the Empire State Building in New York City and emphasizes its national class action securities litigation capabilities [2][3] Group 2 - The firm encourages shareholders with concerns about Coeptis Therapeutics to seek additional information free of charge [3] - Monteverde & Associates PC highlights its litigation experience, including cases that have reached the U.S. Supreme Court [2]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Methanex Corporation and its officers or directors [1]. Group 1: Company Performance and Events - On March 9, 2025, Methanex announced an unplanned outage at its 1.8 million tonne methanol plant, Geismar 3, in Louisiana, which occurred in late February [3]. - Following the outage announcement, Methanex's management decided to repair the autothermal reformer (ATR) and estimated a plant startup by early May 2025 [3]. - The stock price of Methanex fell by $5.45 per share, or 12.9%, closing at $36.80 per share on March 10, 2025, after the announcement [4]. Group 2: Legal and Regulatory Context - Pomerantz LLP, a firm known for its work in corporate, securities, and antitrust class litigation, is leading the investigation into Methanex [5]. - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5].

V i e w p o i n t | 22 Apr 2025 14:12:07 ET │ 10 pages Metal Matters New critical minerals Section 232 poses new US arb upside and opportunities in Pd, Pt, Ni, Zn, Sn CITI'S TAKE 51 metals and minerals are the subject of a new Section 232 (S232) investigation into US critical mineral imports (Fig.1, mostly as published by USGS), reigniting US import tariff risks after broad exemptions for mineral imports from US reciprocal import levies earlier this month. We note particularly the inclusion of palladium, pl ...

Core Viewpoint - Cal-Maine Foods, the largest US egg producer, is under investigation by the Justice Department for potential antitrust violations related to egg price increases, leading to a decline in its stock price by over 4% in after-hours trading [1]. Company Performance - Cal-Maine reported nearly doubled sales of $1.42 billion in its fiscal third quarter ending March 1, primarily driven by higher egg prices, which averaged $4.06 per dozen, up from $2.25 per dozen a year ago [4][7]. - The company sold a record 331.4 million dozen eggs in the third quarter, marking a 10% increase from the same period last year [6]. - Despite the significant increase in sales, Cal-Maine's revenue fell short of Wall Street's forecast of $1.43 billion [4]. Financial Metrics - The net income for Cal-Maine in the third quarter more than tripled to $508.5 million compared to the same period last year, translating to a profit of $10.38 per share, which was below analysts' expectations of $10.72 per share [7]. Industry Context - Egg prices have reached record highs, with one dozen Grade A eggs averaging $5.90 in February, a 10.4% increase from the previous year, surpassing January's record of $4.95 [3]. - The surge in egg prices is largely attributed to a bird flu epidemic that has resulted in the culling of over 166 million birds, primarily egg-laying chickens [3][5].